Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses

Brain, Behavior, and Immunity

Volumn 31, Issue , 2013, Pages 82-89

  Miller, Brian J ^a   Mellor, Andrew ^a   Buckley, Peter ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

C reactive protein; Inflammation; Lymphocytes; Metabolic syndrome; Monocytes; Non affective psychosis; Schizophrenia; WBC

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; LIPID; TRIACYLGLYCEROL;

ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; FEMALE; HOSPITALIZATION; HUMAN; LEUKOCYTE DIFFERENTIAL COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MONOCYTE; PATIENT CARE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; SCHIZOPHRENIA; SMOKING; VITAL SIGN; WAIST CIRCUMFERENCE;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LEUKOCYTE COUNT; LEUKOCYTES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PSYCHOTIC DISORDERS; SCHIZOPHRENIA;

EID: 84878156347     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2012.08.016     Document Type: Article

References (36)

1. Akhondzadeh S., Tabatabaee M., Amini H., Ahmadi Abhair S.A., Abbasi S.H., Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind randomized and placebo-controlled trial. Schizophr. Res. 2007, 90:179-185.
2. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity, 2004. Consensus development conference on antipsychotic drugs and obesity and diabetes. J. Clin. Psychiatr. 65, 267-272.
3. Beumer, W., Drexhage, R.C., De Wit, H., Versnel, M.A., Drexhage, H.A., Cohen, D., 2012. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology [Epub ahead of print]. doi:10.1016/j.psyneuen.2012.04.001.
4. Bhargava P., Lee C.H. Role and function of macrophages in the metabolic syndrome. Biochem. J. 2012, 442:253-262.
5. Carrizo E., Fernández V., Quintero J., Connell L., Rodríguez Z., Mosquera M. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophr. Res. 2008, 103:83-93.
6. Després J.P. Cardiovascular disease under the influence of excess visceral fat. Crit. Pathw. Cardiol. 2007, 6:51-59.
7. Devaraj S., Valleggi S., Siegel D., Jialal I. Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Curr. Atheroscler. Rep. 2010, 12:110-118.
8. Kaptoge S., Di Angelantonio E., Lowe G., Pepys M.B., Thompson S.G., Collins R. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375:132-140. (Emerging Risk Factors Collaboration).
9. Fan X., Liu E.Y., Freudenreich O., Park J.H., Liu D., Wang J., Yi Z., Goff D., Henderson D.C. Higher white blood cell counts are associated with an increased risk for metabolic syndrome and more severe psychopathology in non-diabetic patients with schizophrenia. Schizophr. Res. 2010, 118:211-217.
10. Fawzi M.H., Fawzi M.M., Fawzi M.M., Said N.S. C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia. Psychiatry Res. 2011, 90:91-97.
11. Galassi A., Reynolds K., He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am. J. Med. 2006, 119:812-819.
12. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C., Spertus J.A., Costa F. American heart association; national heart, lung, and blood institute diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation 2005, 112:2735-2752.
13. Kim D.J., Noh J.H., Lee B.W., Choi Y.H., Chung J.H., Min Y.K., Lee M.S., Lee M.K., Kim K.W. The associations of total and differential white blood cell counts with obesity, hypertension, dyslipidemia and glucose intolerance in a Korean population. J. Korean Med. Sci. 2008, 23:193-198.
14. Kushner I., Rzewnicki D., Samols D. What does minor elevation of C-reactive protein signify?. Am. J. Med. 2006, 119:e17-e28.
15. Laan W., Grobbee D.E., Selten J.P., Heijnen C.J., Kahn R.S., Burger H. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2010, 71:520-527.
16. Lao X.Q., Neil Thomas G., Jiang C., Zhang W., Adab P., Lam T.H., Cheng K.K. White blood cell count and the metabolic syndrome in older Chinese: the Guangzhou biobank cohort study. Atherosclerosis 2008, 201:418-424.
17. Masserini C., Vita A., Basile R. Lymphocyte subsets in schizophrenic disorders relationship with clinical, neuromorphological and treatment variables. Schizophr. Res. 1990, 3:269-275.
18. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., Meltzer H.Y., Hsiao J., Scott Stroup T., Lieberman J.A. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005, 80m:19-32.
19. Miller B., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70:663-671.
20. Miller, B.J., Culpepper, N., Rapaport, M.H., 2012. C-Reactive Protein in Schizophrenia: A Review and Meta-Analysis. Clinical Schizophrenia and Related Psychoses.
21. Mitchell, A.J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., De Hert, M., 2011. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders - a systematic review and meta-analysis. Schizophr Bull. (Epub ahead of print). doi:10.1093/schbul/sbr148.
22. Mitchell A.J., Delaffon V., Vancampfort D., Correll C.U., De Hert M. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol. Med. 2012, 42:125-147.
23. Muller N., Riedel M., Scheppach C., Brandstatter B., Sokullu S., Krampe K., et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am. J. Psychiatry 2002, 159:1029-1034.
24. Müller N., Krause D., Dehning S., Musil R., Schennach-Wolff R., Obermeier M., et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr. Res. 2010, 121:118-124.
25. Nakagomi A., Sasaki M., Ishikawa Y., Shibui T., Kosugi M., Endoh Y., Morikawa M., Kusama Y., Atarashi H., Mizuno K. Upregulation of monocyte tissue factor activity is significantly associated with carotid intima-media thickness in patients with metabolic syndrome. J. Atheroscler. Thromb. 2011, 18:475-486.
26. Nakagomi A., Sasaki M., Ishikawa Y., Morikawa M., Shibui T., Kusama Y., Atarashi H., Mizuno K. Upregulation of monocyte tissue factor activity is significantly associated with low-grade chronic inflammation and insulin resistance in patients with metabolic syndrome. Circ. J. 2010, 74:572-577.
27. Natal C., Restituto P., Iñigo C., Colina I., Díez J., Varo N. The proinflammatory mediator CD40 ligand is increased in the metabolic syndrome and modulated by adiponectin. J. Clin. Endocrinol. Metab. 2008, 93:2319-2327.
28. Nurjono M., Lee J. Predictive utility of blood pressure, waist circumference and body mass index for metabolic syndrome in patients with schizophrenia in Singapore. Early Interv. Psychiatr. 2012, 10.1111/j.1751-7893.2012.00384.x.
29. Odagiri K., Uehara A., Mizuta I., Yamamoto M., Kurata C. Longitudinal study on white blood cell count and the incidence of metabolic syndrome. Intern. Med. 2011, 50:2491-2498.
30. Ridker P.M., Danielson E., Fonseca F.A.H., Genest J., Gotto A.M., Kastelein J.J.P. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008, 359:2195-2207. (for the JUPITER Study Group).
31. Saha S., Chant D., McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?. Arch. Gen. Psychiatry 2007, 64:1123-1131.
32. Sperner-Unterweger B., Whitworth A., Kemmler G., et al. T-cell subsets in schizophrenia: a comparison between drug-naïve first episode patients and chronic schizophrenic patients. Schizophr. Res. 1999, 38:61-70.
33. Tsuriya D., Morita H., Morioka T., Takahashi N., Ito T., Oki Y., Nakamura H. Significant correlation between visceral adiposity and high-sensitivity C-reactive protein (hs-CRP) in Japanese subjects. Intern. Med. 2011, 50:2767-2773.
34. Vuksan-Cusa B., Sagud M., Jakovljević M. C-reactive protein and metabolic syndrome in patients with bipolar disorder compared to patients with schizophrenia. Psychiatr. Danub. 2010, 22:275-277.
35. Wilke I., Arolt V., Rothermundt M., et al. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosci. 1996, 246:279-284.
36. Zorrilla E.P., Cannnon T.D., Gur R.E., et al. Leukocytes and organ-nonspecific autoantibodies in schizophrenics and their siblings: markers of vulnerability of disease?. Biol. Psychiatry 1996, 40:825-833.